ArticleClinical and translational science2016

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment.

E Lefebvre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.